(19)
(11) EP 4 240 424 A1

(12)

(43) Date of publication:
13.09.2023 Bulletin 2023/37

(21) Application number: 21802741.5

(22) Date of filing: 04.11.2021
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
A61P 35/00(2006.01)
 A61K 39/395(2006.01)
C07K 16/28(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/6855; A61K 47/6867; A61P 35/00; A61K 47/6831; C07K 2317/21; C07K 2317/76; C07K 16/2827; C07K 16/2803; A61K 39/3955
 
C-Sets:
A61K 39/3955, A61K 2300/00;
(86) International application number:
PCT/EP2021/080688
(87) International publication number:
WO 2022/096604 (12.05.2022 Gazette 2022/19)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 04.11.2020 EP 20205794

(71) Applicant: Heidelberg Pharma Research GmbH
68526 Ladenburg (DE)

(72) Inventors:
  • KULKE, Michael
    68526 Ladenburg (DE)
  • HECHLER, Torsten
    68526 Ladenburg (DE)
  • PAHL, Andreas
    68526 Ladenburg (DE)
  • MÜLLER, Christoph
    68526 Ladenburg (DE)
  • WERNER-SIMON, Susanne
    68526 Ladenburg (DE)

(74) Representative: Michalski Hüttermann & Partner Patentanwälte mbB 
Kaistraße 16A
40221 Düsseldorf
40221 Düsseldorf (DE)

   


(54) COMPOSITION COMPRISING A COMBINATION OF IMMUNE CHECKPOINT INHIBITOR AND ANTIBODY-AMATOXIN CONJUGATE FOR USE IN CANCER THERAPY